SUPPLEMENT NO. 1 TO THE COLLATERAL AGREEMENTCollateral Agreement • March 8th, 2021 • Quotient LTD • In vitro & in vivo diagnostic substances
SUPPLEMENT NO. 1 dated as of March 5, 2021 (this “Supplement”), to the Collateral Agreement dated as of October 14, 2016 (the “Agreement”), among QUOTIENT LIMITED, a public limited liability no par value company incorporated in Jersey, Channel Islands, with registered number 109886 (the “Issuer”), each Subsidiary of the Issuer from time to time party thereto (each such subsidiary, individually, a “Subsidiary Party” and, collectively, the “Subsidiary Parties”; and the Issuer and the Subsidiary Parties are referred to collectively herein as the “Grantors”), U.S. BANK NATIONAL ASSOCIATION, as trustee (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”), and U.S. BANK NATIONAL ASSOCIATION, as collateral agent for the Secured Parties (and its successors under the Indenture, in such capacity, the “Collateral Agent”).
SECOND SUPPLEMENTAL INDENTURESupplemental Indenture • March 8th, 2021 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
THIS SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of March 5, 2021, is among Quotient Iberia, S.L. (the “New Guarantor”), a limited liability company (“Sociedad de Responsabilidad Limitada”) formed under the laws of Spain and a new indirect subsidiary of Quotient Limited (the “Issuer”), the Issuer, the existing guarantors (the “Existing Guarantors”) under the Indenture referred to below, and U.S. Bank National Association, as trustee (the “Trustee”) and as collateral agent (the “Collateral Agent”) under such Indenture.
